DOAC-Stop-L™

DOAC-Stop-L™ is a liquid solution designed to effectively eliminate direct oral anticoagulants (DOACs) from plasma samples, enabling reliable analysis of coagulation parameters.

DOAC-Stop-L™ is the innovative liquid formulation of the well-established DOAC-Stop™, specifically developed for fast, simple, and reliable use in laboratory settings. Using high-affinity activated charcoal, it effectively removes direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban from whole blood or citrated plasma samples.

Following treatment, DOAC-related interferences are eliminated, allowing accurate interpretation of coagulation tests, including:

Detection of coagulation factor deficiencies
Identification of lupus anticoagulants
Assessment of other hemostatic disorders

DOAC-Stop-L™ does not interfere with heparins and is fully compatible with ROTEM and CloPro systems.

Technical Information :

Intended use: For research use only (RUO)
Presentation: Lyophilized vial to be reconstituted with 1.5 mL of water, yielding a final volume of 2 mL
Precautions: For laboratory use only. Not intended for in vitro diagnostic or direct clinical use.

Key Benefits of DOAC-Stop-L™

Effectively removes over 95% of DOACs (dabigatran, apixaban, rivaroxaban, edoxaban)
Easy-to-reconstitute liquid formulation for quick and convenient use
No alteration of coagulation parameters – preserves result integrity
Compatible with multiple assays: ROTEM, CloPro, dRVVT, APTT, and more
Reduces false positives, especially in lupus anticoagulant testing
Cost-effective solution to eliminate analytical interferences and improve test reliability

Informations

The therapeutic use of NOACs is steadily increasing. However, NOACs are known to interfere—often significantly—with most coagulation tests. In some cases, patients requiring testing for underlying coagulation disorders may also be undergoing NOAC therapy.

DOAC-Stop™ is the first general-purpose agent available to address the diagnostic challenges posed by NOACs. After treatment with DOAC-Stop™, plasma samples can be reliably analyzed for underlying coagulation defects, such as factor deficiencies, heparin presence, lupus anticoagulant, or other interfering antibodies.

Documentation

Download the product sheet

Price list, safety data sheets and notices are accessible to our registered customers.

References

20-X9906-100	Flacon	2 mL	100 tests

	These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
	These kits are intended for in vitro diagnostic use.
	These kits are for research use only and are not intended to be used for diagnostic procedures.
	Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
	Biological risk products.
	Storage between 2 and 8 ° C.
	Reactive in liquid form.
	Reactive in lyophilized form.
	Reactive in frozen form.
	Stability after opening at 2-8 ° C.
	Products that can be refrozen.
	Stability 12 months after refreezing at -20 ° C.
	Manufacturer.
	Importer
	Distributor.

You must identify yourself to search for a certificate of analysis

HEMOSTASIS COAGULATION ROUTINE REAGENTS

HEMOSTASIS COAGULATION ROUTINE REAGENTS ANTICOAGULANT MONITORING

HEMOSTASIS COAGULATION ROUTINE REAGENTS AUXILIARY REAGENTS

HEMOSTASIS COAGULATION ROUTINE REAGENTS ANTICOAGULANT MONITORING DOAC

HEMOSTASIS COAGULATION ROUTINE REAGENTS ANTICOAGULANT MONITORING DOAC DOAC NEUTRALIZATION

HEMOSTASIS COAGULATION ROUTINE REAGENTS AUXILIARY REAGENTS NEUTRALIZERS